Chronic Obstructive Pulmonary Disease is a progressive disorder which happens due to cumulative exposure to risk factors, primarily tobacco smoke, along with many other environmental pollutants.
With healthy growth tie ups like 59 licensing and 41 co-development deals pertaining to COPD products since 2006, the Global Chronic Obstructive Pulmonary Disease Market is estimated to grow at a healthy and potential CAGR rate, according to this latest market research report.
Market Driving Factors: new drugs and their new combinations are hoped to bring out a new potential in the overall COPD Market
Chronic obstructive pulmonary disease market is aimed to deal with the chronic inflammation of the airways and lungs. The persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. Thus there is a need for medical therapies and thus there is scope for the Global COPD Market.
Complete research on Chronic Obstructive Pulmonary Disease (COPD) Market available at:
So far, there has been no success in finding the long term cure for the disease but exists only a way to deal and improvise on the COPD symptoms. This lack of robust innovation in the Chronic obstructive pulmonary disease market progression is also driving the market, globally.
Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.
The COPD Drug Market Will Become More Fractured as Several New Agents Reach the Market and Erode the Dominance of the Current Market Leaders. This could hamper the older leaders but the new leaders are expected to increase the market potential with newer and fresher ideas.
Outlook of the Market Trends:
The current COPD pipeline consists of 212 active products in development. Initial analysis revealed a small presence of first-in-class products, constituting 16.5% of the pipeline. The Preclinical Phase of development is the most active in terms of first-in-class products. This diminishes throughout clinical development, with only two such products being present in Phase III. However, if either of these products is approved, they would represent the first, first-in-class products to be approved for COPD since roflumilast, which was approved in 2011 by the FDA and in 2010 in the EU. Roflumilast was the first novel therapy for COPD in almost 20 years, which demonstrates the infrequency at which first-in-class products enter the COPD market. So to have two first-in-class products in Phase III and six in Phase II is a promising sign.
Check research sample here:
Prominent Competitors Brief:
Studies suggest that Pfizer’s Spiriva, GlaxoSmithKline’s (GSK’s) Advair and AstraZeneca’s Symbicort are the current top 3 brands leading the COPD Treatment Market with the proof that they have generated multi-billion dollar revenues until today (the actual numbers of their revenue generations mentioned in the report in detail for each company). The report also includes the estimations of the future sales of these leading players.
Key players analysis, trends of the past, present & growth statistics of future, segmentation in depth, Market drivers, restraints, scope, Future estimations & projections and deep understanding of the leading regions globally as well as their expected growth rates are the major notable offerings in this market report on Chronic Obstructive Pulmonary Disease Drugs Market.
Order a copy of Chronic Obstructive Pulmonary Disease (COPD) Market report at:
On a related note, another research on Frontier Pharma: Parkinson’s Disease – Identifying and Commercializing First-in-Class Innovation available at:
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Company Name: MarketIntelReports
Contact Person: Mayur S.
Address:2711 Centerville Road, Suite 400
Country: United States